Nature of Symptoms in Patients with CAD Predicts Placebo-Controlled Efficacy of PCI: ORBITA-2 Trial Secondary Analysis

Join our community to access additional content!

CRT Community

$0.00

Register for Meetings

“In The News” & “Cardiovascular Marketplace” Content Access

Listen to Podcasts

Watch On-Demand Content

CardioTube Access

Access to Recorded Live Broadcasts from CRTvirtual Meetings, DMV, & Cath Conference

Access Recorded Interviews

Download PPT Slide Decks

Join Now!
Already have an account? Login Now

CRT Community Premium

~~$650.00 annually~~
$455.00 annually
Code: CRT30
Apply code at Checkout Offer Expires: May 31, 2025

Register for Meetings

“In The News” & “Cardiovascular Marketplace” Content Access

Listen to Podcasts

Watch On-Demand Content

CardioTube Access

Access to Recorded Live Broadcasts from CRTvirtual Meetings, DMV, & Cath Conference

Access Recorded Interviews

Download PPT Slide Decks

Complimentary subscription to electronic version of the CRM Journal

Access to CRT Meeting Registration Discounts

CRT Premium Content, including on-demand videos and presentation downloads

Join Now!
Already have an account? Login Now
News

Nature of Symptoms in Patients with CAD Predicts Placebo-Controlled Efficacy of PCI: ORBITA-2 Trial Secondary Analysis

Posted: 05/16/2024
Author:
Bailey Salimes, CRTonline.org
Coronary Imaging & Physiology Coronary Interventions EuroPCR Quality of Life Measures Conference News Percutaneous Coronary Intervention 2024

The nature of symptoms in patients with stable coronary artery disease (CAD) who undergo percutaneous coronary intervention (PCI) is a powerful predictor of the placebo-controlled efficacy of PCI, according to a secondary analysis of the ORBITA-2 trial.
1-3 of 4195 results
1 2 3 4 5 Next »

Newer-Generation DES With Repeat Revascularization Associated With Chronic Stent Recoil: Single-Center Study

Apr 24, 2025 by
Bailey G. Salimes, CRTonline.org

In patients treated with second- or newer-generation drug-eluting stents (DES) who require repeat revascularization, one-fifth of patients have chronic stent recoil, a new study shows.

Early Ezetimibe Treatment Post-MI Reduces Cardiovascular Risk, Study Finds

Apr 24, 2025 by
Will Chu, CRTonline.org

New findings reveal that early administration of ezetimibe with statins following a myocardial infarction (MI) significantly reduces the risk of future cardiovascular events when compared with delayed use or statin monotherapy.

Patients With NSTEMI and Elevated Baseline hsCRP Are at Greater Risk for Cardiovascular Events

Apr 23, 2025 by
Bailey G. Salimes, CRTonline.org

According to a sub-analysis of the PROSPECT II trial, patients with recent non-ST elevation myocardial infarction (NSTEMI) and high baseline levels of high-sensitivity C-reactive protein (hsCRP) are more likely to have pan-coronary atherosclerosis and focal high-risk plaques.

1-3 of 4195 results
1 2 3 4 5 Next »

Most Viewed Pages

Robotic Presentation

The Fellows Call - CRT 2025 Recap

AI in Coronary Artery Interventions: Preprocedural Planning and Procedural Assistance

King and I | S5 E10 | Reflection on the Lancet Commission on Rethinking Coronary Artery Disease

DMV (Apr 2025) Hybrid Technique for Bileaflet Modification in TAVR

Explore the Site

Stay Connected

CRT Group Foundation is a not for profit corporation dedicated to providing educational services in the field of cardiology through the website, CRTonline.org and the Cardiovascular Research Technologies (CRT) annual symposium. CRT focuses on the advances and changes in the field of cardiovascular medicine. CRT is designed to provide access to the world’s leading clinicians and the latest research in order to improve practice and treatment outcomes for a variety of health care professionals.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details

Join our community to access additional content!

CRT Community

CRT Community Premium

News

Nature of Symptoms in Patients with CAD Predicts Placebo-Controlled Efficacy of PCI: ORBITA-2 Trial Secondary Analysis

Newer-Generation DES With Repeat Revascularization Associated With Chronic Stent Recoil: Single-Center Study

Early Ezetimibe Treatment Post-MI Reduces Cardiovascular Risk, Study Finds

Patients With NSTEMI and Elevated Baseline hsCRP Are at Greater Risk for Cardiovascular Events

Most Viewed Pages

Explore the Site

Stay Connected